Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes

Policies:

Cannabis for Medical Purposes

Last updated: 2019-03-03

TOPICS

Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Cannabis for Medical Purposes

Cannabis for Medical Purposes

Last updated: 2019-03-03

POLICY TYPE

Policy document

LAST REVIEWED

2019-03-03

DATE

2010-12-04

POLICY TYPE

Policy document

LAST REVIEWED

2019-03-03

DATE

2010-12-04

TOPICS

Pharmaceuticals, prescribing, cannabis, drugs

Documents

The Canadian Medical Association (CMA) recognizes the unique requirements of those individuals suffering from terminal illness or chronic disease for which conventional therapies have not been effective and for whom legal cannabis (cannabis) use is beneficial.

However, there is not yet sufficient evidence to support its use as a medicinal drug. Questions remain regarding its safety for human use, and the need for further research.

While the information on this issue is evolving and is likely to continue to change, the CMA recommends that healthcare professionals and patients discuss the potential benefits and risks of cannabis use in the context of their individual circumstances.

The CMA endorses the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. This includes research on the impact of cannabis on health and health care, as well as studies to evaluate the potential benefits and risks of cannabis use in particular patient populations.

2. Increase support for appropriate and effective regulatory and policy frameworks that ensure the safe and ethical use of cannabis for medical purposes.

3. Increase support for the development of evidence-based guidelines for the safe and effective use of cannabis in the care of patients with chronic or terminal illnesses.

4. Increase awareness among health care providers, patients, and the public about the potential benefits and risks of cannabis use for medical purposes, including information about available resources and support services.

5. Increase support for the development of educational programs for health care providers to ensure that they are adequately informed about the medical use of cannabis.

The CMA supports the safe and ethical use of cannabis for medical purposes, provided that it is used in accordance with applicable laws and regulations, and that it is administered under the supervision of a qualified health care provider.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE Policy document
LAST REVIEWED 2019-03-03
DATE 2011-05-28
REPLACES Medication use and seniors
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE Policy document
LAST REVIEWED 2019-03-03
DATE 2012-12-08
TOPICS Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents